The Experts below are selected from a list of 72789 Experts worldwide ranked by ideXlab platform
Matthew J Ellis - One of the best experts on this subject based on the ideXlab platform.
-
preoperative endocrine therapy for older women with breast cancer Renewed Interest in an old idea
2000Co-Authors: Matthew J EllisAbstract:Background: Tamoxifen as sole therapy (primary tamoxifen therapy) was investigated in the 1970s and 1980s as an alternative to surgery for older patients with breast cancer. While the majority of primary breast tumors responded to tamoxifen, long-term local disease control was poor. The use of primary tamoxifen therapy is therefore restricted to frail, elderly, and infirm patients who cannot tolerate surgery. In contrast, short-term preoperative endocrine therapy to downstage estrogen receptor-positive (ER+) tumors is under increasing scrutiny as a nontoxic neoadjuvant approach for older women. Methods: The literature on primary tamoxifen therapy and preoperative endocrine therapy was reviewed to construct an opinion piece on the feasibility and safety of preoperative endocrine therapy. Results: A review of nine phase II trials and a meta-analysis of two randomized trials suggest that the initial response rates to preoperative endocrine therapy will exceed 50% to 60% for patients with ER+ disease. A short delay in surgery to administer 3 to 4 months of preoperative endocrine therapy is unlikely to compromise long-term outcomes. Conclusions: Preoperative endocrine therapy is a logical approach for older patients with ER+ disease as a well-tolerated means to increase the rate of breast-conserving surgery. Several clinical trials comparing tamoxifen with selective aromatase inhibitors in the preoperative setting have been conducted, and the results are expected soon. These studies will determine if a large multicenter national trial of preoperative endocrine therapy should be conducted.
Wayne D Tilley - One of the best experts on this subject based on the ideXlab platform.
-
Renewed Interest in the progesterone receptor in breast cancer
2016Co-Authors: Elgene Lim, Carlo Palmieri, Wayne D TilleyAbstract:The progesterone receptor (PgR), a member of the nuclear receptor family, is a well-known oestrogen receptor (ER)-regulated gene that is expressed in over two-thirds of ER-positive (ER+) breast cancers (Rakha et al, 2007). Progesterone receptor (PR) protein generally is assessed by immunohistochemistry at the time of diagnosis in primary breast cancers in most economically developed healthcare systems. PR is more highly expressed in the luminal A breast cancer subtype, and is associated with tumour grade, ER expression, Nottingham Prognostic Group and negative HER2 status in early breast cancer (Arpino et al, 2005; Braun et al, 2013; Purdie et al, 2014). Multiple studies have demonstrated the improved prognosis of PR-positive (PR+) breast cancers (Collet et al, 1996; Bardou et al, 2003; Viale et al, 2007; Blows et al, 2010; Van Belle et al, 2010; Purdie et al, 2014).
Robert J Cotter - One of the best experts on this subject based on the ideXlab platform.
-
glycoproteomics new technology developments and applications provide Renewed Interest in glycoproteins
2008Co-Authors: Hui Zhang, Robert J CotterAbstract:Glycoproteins are formed through covalent linkages of sugar residues to specific amino acids in proteins. Both amide and acyl linkages are possible, and the resultant Nglycosylated and O-glycosylated proteins carry remarkable complexity in their oligosaccharide chains. N- and O-glycosylations occur in proteins that remain in the endoplasmic reticulum, proteins in the plasma membrane, and proteins secreted into the extracellular surface. Nglycosylation is localized to Asn residues, in the consensus tripeptide sequence Asn-X-Ser/Thr (X is any amino acid except proline). O-glycosylation of proteins occurs commonly on both Ser and Thr residues, as well as posttranslational hydroxylation-created 5-hydroxylysine and 4-hydroxyproline side chains. There are reports of glycosylation to Cys residues. O-linked β-N-acetylglucosamine (O-GlcNAc) is a modification of serine or threonine side chains of nuclear and cytoplasmic proteins [1]. The study of glycoproteins began a very long time ago; progress in understanding their structure and function has awaited the development of methods for the isolation of glycoproteins and glycans and the analysis of the sequences of residues in both polysaccharides and polypeptides. The field of “glycoproteomics” has emerged recently from the global analyses of structures and functions of glycoproteins, similar to the approaches now used in “proteomics.” The
Jonathan A Godin - One of the best experts on this subject based on the ideXlab platform.
-
anterolateral knee extra articular stabilizers a robotic study comparing anterolateral ligament reconstruction and modified lemaire lateral extra articular tenodesis
2018Co-Authors: Andrew G Geeslin, Gilbert Moatshe, Jorge Chahla, Bradley M Kruckeberg, Kyle J Muckenhirn, Grant J Dornan, Ashley Coggins, Alex W Brady, Alan Getgood, Jonathan A GodinAbstract:Background:Persistent clinical instability after anterior cruciate ligament (ACL) reconstruction may be associated with injury to the anterolateral structures and has led to Renewed Interest in ant...
C Garrone - One of the best experts on this subject based on the ideXlab platform.
-
preoperative pneumatic dilatation represents a risk factor for laparoscopic heller myotomy
1997Co-Authors: M Morino, F Rebecchi, V Festa, C GarroneAbstract:Background: The development of minimally invasive surgery has Renewed Interest in the surgical therapy of achalasia.
